Search
Close this search box.
Logo Asphalion
crispr

First patients treated with CRISPR

The University of Pennsylvania in Philadelphia, USA, reported that the first two patients in a cancer immunotherapy trial have received CRISPR-edited medicinal product.

The University of Pennsylvania in Philadelphia, USA, reported that the first two patients in a cancer immunotherapy trial have received CRISPR-edited medicinal product.
May 13, 2019

The University of Pennsylvania in Philadelphia, USA, reported that the first two patients in a cancer immunotherapy trial have received CRISPR-edited medicinal product.

In this protocol, CRISPR is not applied in vivo, but ex vivo to eliminate three endogenous genes, the α and β chains of the endogenous T cell receptor (TCR) and Programmed Cell Death Protein-1 (PD-1), whereas a lentivirus is used to introduce into autologous T Cells a T cell receptor targeting the cancer antigen NY-ESO-1. The rationale for using CRISPR to supplement the chimeric T cell receptor approach is to reduce the risk of autoimmunity, reduce TCR mispairing and promote the expression of exogenous NY-ESO-1 TCR.

This data will represent the first safety data for CRISPR in properly controlled and regulated human studies.

Search News & Events

  • Filter by category

Share

Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting